Athersys has been granted a patent for a method to treat wounds by applying specific cells directly to the wound without the need for a functionalized substrate. The method aims to promote cutaneous burn healing in subjects using non-embryonic non-germ cells with specific characteristics. GlobalData’s report on Athersys gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Athersys Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Athersys, Human telomerase RT biomarker was a key innovation area identified from patents. Athersys's grant share as of April 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.

Method for treating cutaneous burn wounds using non-embryonic cells

Source: United States Patent and Trademark Office (USPTO). Credit: Athersys Inc

A recently granted patent (Publication Number: US11918609B2) discloses a method for promoting cutaneous burn healing in a subject by administering specific cells in an effective amount and for a sufficient duration. These cells, referred to as cells (I), are non-embryonic non-germ cells that express CD90 and either oct4 or telomerase. Importantly, these cells are not transformed, tumorigenic, and possess a normal karyotype, ensuring their safety and efficacy in promoting healing.

Furthermore, the patent claims specify various aspects of the method, including the ability of the cells to differentiate into different cell types, the source of the cells (such as bone marrow or human-derived), the method of administration (topical, subcutaneous, injection), and the use of liquid cell suspension or reservoir for delivery. The method outlined in the patent aims to address cutaneous burns on the skin and underlying tissues, highlighting the potential of these specific cells in promoting healing in such conditions. Additionally, the patent emphasizes that the cells (I) are not genetically manipulated, further ensuring their natural and safe application in promoting cutaneous burn healing.

To know more about GlobalData’s detailed insights on Athersys, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies